Fairvalue-Calculator Fairvalue-Calculator
EN DE

Boule Diagnostics AB (BOUL) Fair Value & Analysis

Healthcare · SE · Market cap 122M SEK

Pricekr 3.46
Fair Valuekr 2.62
Upside-24.3%
Quality95/100
Evidence: Medium Range kr 2.62 – kr 2.98

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Boule Diagnostics AB (BOUL) currently trades at kr 3.46, while our model-based Fair Value estimate is kr 2.62 — implying the stock looks roughly 24.3% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Boule Diagnostics AB (publ) develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. The company provides hematology analyzers, reagents, controls, and calibrators, under the Swelab, and Medonic brands; and veterinary hematology and clinical chemistry analyzer systems, as well as reagents and panels under the Exigo brand. It serves small and medium-sized hospitals, clinics, laboratories, and veterinary clinics, and other diagnostics firms. The company was founded in 1956 and is headquartered in Spånga, Sweden.

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABT) -23% Stryker Corporation (S1YK34) -89% Medtronic plc (MDT) -9% Boston Scientific Corporation (B1SX34) -83% Edwards Lifesciences Corporation (EW) -53% Siemens Healthineers AG (SEMHF) +11%

Frequently asked questions

Is Boule Diagnostics AB (BOUL) undervalued?
As of Jun 24, 2026, our model estimates a fair value of kr 2.62 versus a price of kr 3.46 — about −24% (overvalued). Model-based estimate, not financial advice.
What is the fair value of BOUL?
Our 21-model fair value for Boule Diagnostics AB is kr 2.62 (as of Jun 24, 2026), built from audited fundamentals. The current price is kr 3.46.
What is the quality score of BOUL?
Boule Diagnostics AB has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.